Welcome to our dedicated page for Monte Rosa Therapeutics news (Ticker: GLUE), a resource for investors and traders seeking the latest updates and insights on Monte Rosa Therapeutics stock.
Monte Rosa Therapeutics develops molecular glue degrader medicines for serious diseases using its QuEEN discovery engine, which combines AI-guided chemistry, chemical libraries, structural biology and proteomics. The company’s news centers on clinical and preclinical updates for programs including MRT-8102, a NEK7-directed degrader for inflammatory disease biology; MRT-2359, a GSPT1-directed degrader studied in metastatic castration-resistant prostate cancer; and MRT-6160, a VAV1-directed degrader for immune-mediated diseases.
Recurring developments also include oncology discovery work such as cyclin E1-directed and CDK2-directed degrader programs, clinical supply and pharmaceutical collaboration activity, quarterly financial results, equity awards, capital resources and public-company governance updates.
Monte Rosa Therapeutics (GLUE) announced that collaborator Novartis has initiated a Phase 2 clinical study of VAV1-directed molecular glue degrader MRT-6160 (DDY391) in participants with Sjögren’s disease, triggering a $50 million milestone payment to Monte Rosa.
The Phase 2a/b randomized, double-blind, placebo-controlled, multi-center trial will evaluate up to 52 weeks of MRT-6160 treatment to assess efficacy, safety and tolerability and to support Phase 3 dose selection. The study, titled “A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease,” is listed as NCT07737743 on ClinicalTrials.gov.
Under a global exclusive license, Novartis holds worldwide rights and funds Phase 2 development, while Monte Rosa remains eligible for up to $2.1 billion in development, regulatory and sales milestones and a 30% share of U.S. profits and losses for MRT-6160, plus tiered ex-U.S. royalties.
Monte Rosa Therapeutics (GLUE) granted inducement equity awards to six newly hired non-executive employees under its 2026 Inducement Plan. The grants include non-qualified stock options to purchase an aggregate of 31,145 shares of common stock at an exercise price of $14.31 per share, equal to the Nasdaq closing price on September 1, 2026, the Grant Date. These options vest 25% on the first anniversary of the Grant Date and monthly in 36 equal installments thereafter, subject to continued service. The employees also received an aggregate of 6,440 restricted stock units, vesting 25% annually over four years from the Grant Date, subject to continued service. The awards were granted outside stockholder-approved equity plans, approved by the board’s independent compensation committee, and are intended as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Monte Rosa Therapeutics (Nasdaq: GLUE) announced that its management will participate in two September 2026 investor events: a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 10, 2026 at 12:45 p.m. ET, and the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14, 2026.
A live webcast of the Wells Fargo fireside chat and a 30-day archive will be available in the “Events & Presentations” section of Monte Rosa’s investor relations website.
Monte Rosa Therapeutics (Nasdaq: GLUE) announced dosing of the first patient in MODeFIRe-1 (NCT07745361), a Phase 2 trial of investigational molecular glue degrader MRT-2359 plus apalutamide in patients with AR mutation-positive metastatic castration-resistant prostate cancer (mCRPC).
The study will enroll up to 25 mCRPC patients with AR mutations previously treated with a second-generation AR inhibitor and will assess PSA and RECIST responses, duration of response, rPFS, PSA progression-free survival, and safety. According to Monte Rosa, prior Phase 1/2 combination data with enzalutamide in heavily pretreated advanced CRPC showed PSA responses in 5/5 AR-mutant patients, a 100% disease control rate, and two RECIST responses. Enrollment in that expansion arm is complete, and an updated data readout on six AR-mutant patients is planned by year-end.
Monte Rosa Therapeutics (Nasdaq: GLUE) reported second quarter 2026 results and pipeline progress, highlighted by completion of enrollment and dosing in the GFORCE-1 Phase 1 study of MRT-8102 in subjects with elevated cardiovascular disease risk, with a data readout expected in H2 2026.
The company activated the MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide in mCRPC, and Novartis activated a Phase 2 trial of MRT-6160 (DDY391) in Sjögren’s disease under a global license that could deliver up to $2.1 billion in milestones.
For Q2 2026, collaboration revenue was $9.0 million, R&D expenses were $48.0 million, G&A expenses were $10.1 million, and net loss was $43.4 million. Monte Rosa ended the quarter with $626.0 million in cash, cash equivalents, restricted cash, and marketable securities, which it expects to fund operations into 2029.
Monte Rosa Therapeutics (Nasdaq: GLUE) granted inducement equity awards to three new non-executive employees under its 2026 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4).
Awards include options on 18,025 shares at $24.02 and 3,900 restricted stock units with multi-year vesting.
Monte Rosa Therapeutics (Nasdaq: GLUE) granted inducement equity awards to four new non-executive employees under its 2026 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4).
The awards include options for 20,050 shares at $19.67 and 4,400 restricted stock units, with multi-year, service-based vesting schedules.
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech focused on molecular glue degrader medicines, will join two investor events. Management will participate in fireside chats at the TD Cowen 7th Annual Oncology Innovation Summit on May 27, 2026, and the Jefferies Global Healthcare Conference on June 4, 2026.
Live webcasts and 30-day archives will be available in the Events & Presentations section of the company’s investor relations website.
Monte Rosa Therapeutics (Nasdaq: GLUE) reported Q1 2026 results and program updates on May 7, 2026. Key clinical highlights include MRT-8102 interim data showing CRP -85% and 94% of subjects below 2 mg/L, MRT-2359 tumor activity in mCRPC, and preclinical CCNE1 program with IND planned in H2 2026. Financially, cash and marketable securities were $671.2M, expected to support operations into 2029.
Monte Rosa Therapeutics (Nasdaq: GLUE) granted inducement equity awards to four newly hired non-executive employees under its 2026 Inducement Plan on May 1, 2026. The awards include non-qualified stock options for 38,925 shares at an $18.80 exercise price and 8,550 restricted stock units, with standard time-based vesting.